State Street SPDR S&P Pharmaceuticals ETF XPH
Source: Yahoo Finance (opens in a new tab) Observed · 1 day ago Quotes may be delayed
- Expense ratio
- 0.35%
- Net assets
- $428.4M
- Holdings
- 67
- 12-month distribution yield
- 0.43%
- Asset class
- Equity
State Street SPDR S&P Pharmaceuticals ETF (XPH) is an exchange-traded fund listed on NYSE Arca in the United States, issued by State Street. Its category is Equity · US (equity). Its last price was US$64.15 on 20 Oct 2026. Its expense ratio is 0.35% a year, from its prospectus dated 31 Oct 2025. It reported net assets of US$428.43 million as of 30 Jun 2026. Its latest holdings report lists 67 holdings as of 30 Jun 2026. Over the last 12 months it paid distributions of US$0.28 a unit, a 12-month distribution yield of 0.43%, paid quarterly.
Fees
- Total annual operating expenses (gross)
- 0.35%
- Net, after fee waivers or reimbursements
- No waiver stated
- Management fee
- 0.35%
- Prospectus date
- 31 Oct 2025
- Filed with the SEC
- 24 Oct 2025
Size and reporting
- Net assets
- $428,431,440
- Total assets
- $465,293,105
- Holdings as of
- 30 Jun 2026
- Report made public
- 28 Aug 2026 (59 days after the month end)
Top holdings
Largest 25 of 67 positions, as of 30 Jun 2026. Weight is the percent of net assets the fund reported.
| # | Holding | Identifier | Weight | Value (USD) | Type | Country | Currency |
|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors State Street Navigator Securities Lending Portfolio II | US8574927062 | 8.58% | $36.8M | Short-term investment vehicles (cash funds) | United States | USD |
| 2 | Definium Therapeutics Inc | CA24477V1058 | 3.09% | $13.2M | Equity (common) | Canada | USD |
| 3 | MBX Biosciences Inc | US55287L1017 | 2.72% | $11.6M | Equity (common) | United States | USD |
| 4 | Alumis Inc | US0223071020 | 2.14% | $9.2M | Equity (common) | United States | USD |
| 5 | AtaiBeckley Inc | US04650F1012 | 2.13% | $9.1M | Equity (common) | United States | USD |
| 6 | Trevi Therapeutics Inc | US89532M1018 | 2.12% | $9.1M | Equity (common) | United States | USD |
| 7 | Enliven Therapeutics Inc | US29337E1029 | 2.09% | $9.0M | Equity (common) | United States | USD |
| 8 | Amylyx Pharmaceuticals Inc | US03237H1014 | 2.04% | $8.7M | Equity (common) | United States | USD |
| 9 | VeraDermics Inc | US9229671048 | 2.02% | $8.6M | Equity (common) | United States | USD |
| 10 | Ligand Pharmaceuticals Inc | US53220K5048 | 1.94% | $8.3M | Equity (common) | United States | USD |
| 11 | Nuvation Bio Inc | US67080N1019 | 1.89% | $8.1M | Equity (common) | United States | USD |
| 12 | Edgewise Therapeutics Inc | US28036F1057 | 1.88% | $8.1M | Equity (common) | United States | USD |
| 13 | Nektar Therapeutics | US6402683063 | 1.88% | $8.0M | Equity (common) | United States | USD |
| 14 | Liquidia Corp | US53635D2027 | 1.86% | $8.0M | Equity (common) | United States | USD |
| 15 | Maze Therapeutics Inc | US5787841007 | 1.85% | $7.9M | Equity (common) | United States | USD |
| 16 | Harrow Inc | US4158581094 | 1.81% | $7.7M | Equity (common) | United States | USD |
| 17 | EyePoint Inc | US30233G2093 | 1.77% | $7.6M | Equity (common) | United States | USD |
| 18 | Amneal Pharmaceuticals Inc | US03168L1052 | 1.72% | $7.4M | Equity (common) | United States | USD |
| 19 | Ocular Therapeutix Inc | US67576A1007 | 1.71% | $7.3M | Equity (common) | United States | USD |
| 20 | Corcept Therapeutics Inc | US2183521028 | 1.70% | $7.3M | Equity (common) | United States | USD |
| 21 | Crinetics Pharmaceuticals Inc | US22663K1079 | 1.66% | $7.1M | Equity (common) | United States | USD |
| 22 | Pacira BioSciences Inc | US6951271005 | 1.65% | $7.1M | Equity (common) | United States | USD |
| 23 | Merck & Co Inc | US58933Y1055 | 1.65% | $7.1M | Equity (common) | United States | USD |
| 24 | Indivior Pharmaceuticals Inc | US45579U1097 | 1.64% | $7.0M | Equity (common) | United States | USD |
| 25 | Elanco Animal Health Inc | US28414H1032 | 1.64% | $7.0M | Equity (common) | United States | USD |
Breakdowns
Sums of reported weights over every position in the report. Totals can differ from 100% because of derivatives, borrowing and cash.
Asset type
| Type | Weight | Bar |
|---|---|---|
| Equity (common) | 99.95% | |
| Short-term investment vehicles (cash funds) | 8.64% |
Country
| Country | Weight | Bar |
|---|---|---|
| United States | 98.39% | |
| Canada | 3.09% | |
| Ireland | 3.02% | |
| United Kingdom | 1.57% | |
| Singapore | 1.57% | |
| Cayman Islands | 0.96% |
Currency exposure
| Currency | Weight | Bar |
|---|---|---|
| US dollar (USD) | 108.59% |
Sector
| Sector | Weight | Bar |
|---|---|---|
| Health Care | 27.25% | |
| Health Technology | 1.66% |
Source: SEC Form N-PORT (opens in a new tab) Holdings as of
Distributions
- Paid in the last 12 months
- $0.2750
- 12-month yield
- 0.43%
- Frequency
- Quarterly
- Latest ex-date
- 21 Sep 2026
12-month yield = distributions per unit with an ex-date in the last 12 months ($0.2750) ÷ latest price ($64.15) × 100 = 0.43%. It looks back, so it is not a forecast; special distributions in the window are included.
Why a distribution yield is not the fund's return: yield vs total return
Distribution history table (20 payments)
| Ex-date | Amount per unit |
|---|---|
| 21 Sep 2026 | $0.0420 |
| 22 Jun 2026 | $0.0590 |
| 23 Mar 2026 | $0.0610 |
| 22 Dec 2025 | $0.1130 |
| 22 Sep 2025 | $0.1030 |
| 23 Jun 2025 | $0.0960 |
| 24 Mar 2025 | $0.1530 |
| 23 Dec 2024 | $0.1550 |
| 23 Sep 2024 | $0.1950 |
| 24 Jun 2024 | $0.1560 |
| 18 Mar 2024 | $0.1730 |
| 18 Dec 2023 | $0.1740 |
| 18 Sep 2023 | $0.1200 |
| 20 Jun 2023 | $0.1240 |
| 20 Mar 2023 | $0.1150 |
| 19 Dec 2022 | $0.1940 |
| 19 Sep 2022 | $0.1320 |
| 21 Jun 2022 | $0.1650 |
| 21 Mar 2022 | $0.1810 |
| 20 Dec 2021 | $0.1940 |
Filings and sources
- Form N-PORT report for June 2026 (opens in a new tab)
- Prospectus filing with the fee table (opens in a new tab)
- All SEC filings for this fund series (S000012321) (opens in a new tab)
- Nasdaq Trader symbol directory (opens in a new tab)
- Yahoo Finance quote and distributions (opens in a new tab)
- How the ETF figures are collected
Compare with
Largest funds in the same category:
- XPH and VTI Vanguard Morningstar Total Stock Market ETF
- XPH and VOO Vanguard S&P 500 ETF
- XPH and IVV iShares Core S&P 500 ETF
- XPH and QQQ Invesco QQQ Trust, Series 1